FitLife Manufacturers, Inc. FTLF is seeing a slowdown in shopper spending on dietary dietary supplements and wellness merchandise. This Zacks Rank #5 (Robust Promote) is anticipated to see earnings decline in 2026.
FitLife Manufacturers develops proprietary dietary dietary supplements and wellness merchandise for health-conscious customers. It markets greater than 500 completely different merchandise on-line and thru varied retail areas.
A few of its manufacturers embrace Dr. Tobias, PMD, Siren Labs, MusclePharm, and Maritime Naturals.
FitLife Manufacturers Sees Massive Development for Irwin on Amazon
On Aug 8, 2025, FitLife Manufacturers acquired Irwin Naturals. It put Irwin merchandise on Amazon in Oct 2025, the place it started at zero gross sales. It scaled to roughly $0.5 million within the month of December.
Subsequent to the tip of the fourth quarter 2025, Irwin income on Amazon continued to scale to roughly $0.8 million month-to-month. This was additionally at margins greater than their conventional wholesale enterprise.
A key initiative for 2026 is to leverage Irwin’s gross sales crew to cross-sell Irwin’s different manufacturers throughout the wholesale channel.
Shopper Slows Down in 2026
FitLife Manufacturers reported fourth quarter 2025 outcomes on Apr 1, 2026, so it already had seen the outcomes of the primary few months of the brand new yr.
“Throughout our previousearnings callin November, I supplied commentary about rising weak point we had been observing throughout our model portfolio. In the course of the first quarter of 2026, this weak point has endured throughout most manufacturers and channels,” stated Dayton Judd, Chairman and CEO.
“From a macro surroundings perspective, given the backdrop of financial and political volatility, we all know there are broad-based shopper confidence considerations, significantly for discretionary merchandise,” he added.
Earnings Estimates are Slashed for 2026 and 2027
It shouldn’t be a shock, given the corporate’s gloomy outlook on the patron, that the earnings estimates have been reduce.
FitLife is a small cap firm with a market cap of simply $87.5 million. Zacks solely has estimates from one analyst.
That analyst reduce the 2026 and 2027 earnings estimate within the final 30 days. For 2026, it fell to $0.86 from $1.62. That’s an earnings decline of 8.5% as FitLife made $0.94 in 2025.
The 2027 earnings consensus additionally fell to $1.19 from $1.82 within the prior month. However that’s an earnings acquire of 38.4%.
Nonetheless, each of those had been massive cuts to the estimates. Right here’s what it seems to be like on the worth and consensus chart.
Picture Supply: Zacks Funding Analysis
Shares of FitLife Slide in 2026
Given all of the uncertainty concerning the shopper this yr, it’s not a shock that the shares have slid in 2026. They’re at 52-week lows.
Picture Supply: Zacks Funding Analysis
However FitLife is now low cost. It trades with a ahead price-to-earnings (P/E) ratio of 10.8. A P/E beneath 15 often means an organization has worth.
It additionally has different enticing valuations like a price-to-book (P/B) ratio of simply 2. A P/B ratio of three.0 and beneath often means an organization is undervalued.
As of Dec 31, 2025, FitLife had $39.1 million excellent on its time period mortgage and $5.6 million excellent on the revolver. FitLife’s money was $1.6 million, giving it a complete internet debt of $43.1 million.
For buyers seeking to put money into a wellness firm, it is perhaps finest to remain on the sidelines with FitLife Manufacturers till the patron begins shopping for once more.
Past Nvidia: AI’s Second Wave Is Right here
The AI revolution has already minted millionaires. However the shares everybody is aware of about aren’t more likely to maintain delivering the largest income. Little-known AI corporations tackling the world’s largest issues could also be extra profitable within the coming months and years.
FitLife Manufacturers Inc. (FTLF) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
